Sage Therapeutics, Inc. (SG7.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 04:08PM CEST
| Previous close | 13.12 |
| Open | 12.55 |
| Bid | 12.64 x N/A |
| Ask | 12.71 x N/A |
| Day's range | 12.55 - 12.72 |
| 52-week range | 11.45 - 55.00 |
| Volume | |
| Avg. volume | 47 |
| Market cap | 767.047M |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.82 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 85.05 |
Simply Wall St.Earnings Update: Sage Therapeutics, Inc. (NASDAQ:SAGE) Just Reported And Analysts Are Boosting Their Estimates
Investors in Sage Therapeutics, Inc. ( NASDAQ:SAGE ) had a good week, as its shares rose 2.7% to close at US$13.69...
ZacksSage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Simply Wall St.Sage Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Sage Therapeutics ( NASDAQ:SAGE ) First Quarter 2024 Results Key Financial Results Revenue: US$7.90m (up 140% from 1Q...
© 2024 Yahoo. All rights reserved.